Embracing the Landscape of Therapeutics.
出版信息
Cell. 2020 Apr 2;181(1):1-3. doi: 10.1016/j.cell.2020.03.025.
Abstract
摘要
相似文献
1
Embracing the Landscape of Therapeutics.
Cell. 2020 Apr 2;181(1):1-3. doi: 10.1016/j.cell.2020.03.025.
2
Drug-drug similarity measure and its applications.
Brief Bioinform. 2021 Jul 20;22(4). doi: 10.1093/bib/bbaa265.
3
In silico drug repositioning: from large-scale transcriptome data to therapeutics.
Arch Pharm Res. 2019 Oct;42(10):879-889. doi: 10.1007/s12272-019-01176-3. Epub 2019 Sep 3.
4
Changes on the Horizon for Drug Repurposing, Rescue, and Repositioning at ASSAY.
Assay Drug Dev Technol. 2018 May/Jun;16(4):193. doi: 10.1089/adt.2018.29074.edi. Epub 2018 Jun 5.
5
The Drug Repurposing Hub: a next-generation drug library and information resource.
Nat Med. 2017 Apr 7;23(4):405-408. doi: 10.1038/nm.4306.
6
Relating anatomical therapeutic indications by the ensemble similarity of drug sets.
J Chem Inf Model. 2013 Aug 26;53(8):2154-60. doi: 10.1021/ci400155x. Epub 2013 Aug 12.
7
Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases.
Drug Discov Today. 2019 Apr;24(4):1010-1016. doi: 10.1016/j.drudis.2019.01.010. Epub 2019 Jan 25.
8
A Prospective Overview of Drug Repurposing in Drug Discovery and Development.
Curr Med Chem. 2019;26(28):5338-5339. doi: 10.2174/092986732628191025094454.
9
Editorial: computational methods for drug repurposing.
Brief Bioinform. 2011 Jul;12(4):301-2. doi: 10.1093/bib/bbr047.
10
Drug repurposing a reality: from computers to the clinic.
Expert Rev Clin Pharmacol. 2013 Mar;6(2):95-7. doi: 10.1586/ecp.12.79.
引用本文的文献
1
SARS-CoV-2 Virus and Human Leukocyte Antigen (HLA) Class II: Investigation in silico of Binding Affinities for COVID-19 Protection and Vaccine Development.
J Immunol Sci. 2020 Nov 16;4(4):12-23. doi: 10.29245/2578-3009/2020/4.1198.
2
Natural medicinal plant products as an immune-boosters: A possible role to lessen the impact of Covid-19.
Case Stud Chem Environ Eng. 2021 Dec;4:100105. doi: 10.1016/j.cscee.2021.100105. Epub 2021 May 5.
3
Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2.
Viruses. 2024 Feb 22;16(3):338. doi: 10.3390/v16030338.
4
Current Healthcare Systems in Light of Hyperendemic NCDs and the COVID-19 Pandemic: Time to Change.
Healthcare (Basel). 2023 May 10;11(10):1382. doi: 10.3390/healthcare11101382.
5
Multi-target antibacterial mechanism of ruthenium polypyridine complexes with anthraquinone groups against .
RSC Med Chem. 2023 Feb 7;14(4):700-709. doi: 10.1039/d2md00430e. eCollection 2023 Apr 26.
6
Medicine and health of 21st Century: Not just a high biotech-driven solution.
NPJ Genom Med. 2022 Nov 15;7(1):67. doi: 10.1038/s41525-022-00336-7.
7
Perspective of AI system for COVID-19 detection using chest images: a review.
Multimed Tools Appl. 2022;81(15):21471-21501. doi: 10.1007/s11042-022-11913-4. Epub 2022 Mar 15.
8
The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.
Ther Clin Risk Manag. 2020 Oct 20;16:1007-1022. doi: 10.2147/TCRM.S272908. eCollection 2020.
9
Repurposing existing drugs for COVID-19: an endocrinology perspective.
BMC Endocr Disord. 2020 Sep 29;20(1):149. doi: 10.1186/s12902-020-00626-0.
10
SARS-CoV-2 envelope protein topology in eukaryotic membranes.
Open Biol. 2020 Sep;10(9):200209. doi: 10.1098/rsob.200209. Epub 2020 Sep 9.
Zotero 插件